doxazosin mesylate / Generic mfg. - LARVOL DELTA

Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). (PubMed, Aging Male) - "Reports of adverse events (AEs) in male BPH patients receiving AUA guideline-recommended drugs including α-1 blockers (tamsulosin, silodosin, doxazosin, and alfuzosin), 5ARIs (finasteride and dutasteride), and tadalafil were extracted. Sixteen significant AEs were detected, including pollakiuria, gynecomastia, breast pain and so on, with distinct reporting patterns across drug classes. This large-scale pharmacovigilance analysis identified distinct post-marketing safety signals among guideline-recommended pharmacotherapies for BPH, confirming known risks and suggesting potential novel adverse-event signals warranting further investigation."

Adverse events • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia • Pain

Physiologically based pharmacokinetic modeling of immediate-release and extended-release formulations of doxazosin, an alpha-1 adrenergic receptor antagonist, with model simulations for patients with liver disease. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The PBPK model developed in this study serves as a practical tool for quantitatively predicting the PK of doxazosin across different formulations and varying degrees of liver impairment. It holds potential for supporting the development of patient-tailored treatment strategies in the future."

Journal • PK/PD data • Benign Prostatic Hyperplasia • Cardiovascular • Hepatology • Hypertension • ADRA1B

Old Molecules, New Hope: A Scoping Review and Bibliometric Analysis of Drug Repurposing for Lung Cancer. (PubMed, Chem Biol Interact) - "Frequently studied drugs included niclosamide, metformin, atorvastatin, and doxazosin, targeting pathways such as PI3K/AKT/mTOR, apoptosis, and autophagy. Progress in this field depends on integrating diverse methodologies and fostering interdisciplinary collaboration. As a next step, rigorous clinical trials are essential to confirm the efficacy and safety of promising repurposed agents in oncology."

Journal • Review • CNS Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

DOXY: Alpha-1 Blockade for Alcohol Use Disorder (AUD) (clinicaltrials.gov) - P2 | N=184 | Recruiting | Sponsor: Brown University | Trial completion date: Dec 2025 ➔ Aug 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Addiction (Opioid and Alcohol)

Management of trauma-related nightmares in PTSD: Can doxazosin serve as a pragmatic alternative to prazosin? (PubMed, Encephale) - "Doxazosin may represent a pragmatic pharmacological option for managing TRNs in PTSD, especially in the context of prazosin withdrawal. Its use should complement, rather than replace, first-line psychotherapeutic approaches and be integrated into a comprehensive, coordinated, and individualized treatment plan with careful monitoring of adverse effects. Larger, well-designed randomized controlled trials are needed to determine optimal dosing, treatment duration, and predictors of response."

Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

PHEOCHROMOCYTOMA-INDUCED ATYPICAL TAKOTSUBO CARDIOMYOPATHY PRESENTING AS HYPERTENSIVE CRISIS (ACC 2026) - "Treatment included doxazosin, nitroglycerin infusion, and intravenous diuretics. PHEO should be considered in the setting of hypertensive crisis, acute pulmonary edema, and new-onset cardiomyopathy, especially with basal LV involvement. Early alpha-blockade, hemodynamic support, and adrenalectomy can lead to rapid functional recovery and mitigate morbidity."

Cardiomyopathy • Cardiovascular • Dyslipidemia • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

REVERSING HEART FAILURE FROM AFAR: MULTIDISCIPLINARY MANAGEMENT AND REMOTE MONITORING IN A PATIENT WITH PHEOCHROMOCYTOMA-INDUCED CARDIOMYOPATHY (ACC 2026) - "Decision-Making: The patient was transitioned from beta-blockade to alpha-blockade (doxazosin) before resuming carvedilol, achieving blood pressure stabilization. This case highlights the importance of a multidisciplinary approach and the role of RPM in bridging geographical gaps for patients with rare and complex conditions. Through coordinated cardiology, endocrinology, and surgical care, pheochromocytoma-induced cardiomyopathy was fully reversed, enabling the patient to return to normal life and safely consider pregnancy. RPM proved instrumental in maintaining continuity, optimizing therapy, and ensuring recovery."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diabetes • Endocrine Disorders • Heart Failure • Hypertension • Metabolic Disorders • Pulmonary Disease • Solid Tumor • Type 2 Diabetes Mellitus • FH

EXPLORING INTERVENTIONAL THERAPIES IN RESISTANT HYPERTENSION: DUAL RENAL REVASCULARIZATION AND DENERVATION (ACC 2026) - "Case: A 62 year old woman with a 20-year history of resistant hypertension on five antihypertensive agents (including amlodipine, doxazosin, hydralazine, isosorbide mononitrate, and torsemide) followed with hypertension clinic due to ongoing difficulty controlling blood pressures at home. Our case presents a unique application of dual renal therapy with renal artery stenting and renal sympathetic denervation."

Atherosclerosis • Cardiovascular • Hypertension • Nephrology • Renal Disease • Respiratory Diseases

PARAGANGLIOMA-INDUCED PERIOPERATIVE TAKOTSUBO CARDIOMYOPATHY PRESENTING WITH VENTRICULAR ARRHYTHMIA (ACC 2026) - "She was discharged on sacubitril-valsartan and metoprolol but re-presented within 24 hours with chest pain, dyspnea, labile blood pressure, and reported episodic headaches and palpitations for one year...Doxazosin was initiated for preoperative optimization with endocrine follow-up. PPGL-induced TCM can present with severe complications including life-threatening arrhythmias, cardiogenic shock and heart failure, which should prompt suspicion for occult catecholamine-secreting tumors. Timely diagnosis is essential to improving outcomes."

Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Depression • Gastroenterology • Heart Failure • Pulmonary Disease • Solid Tumor

From Weight Loss to Kidney Loss: Off-Label Semaglutide-Induced Acute Kidney Injury (UKKW 2026) - "Three doses of IV methylprednisolone 250 mg were given, which lead to improved kidney function...In Day 23 follow up, Doxazosin was stopped...Further research and reported cases are needed to understand individual risk factors for AKI in GLP-1RA use. The rise in off-label use is concerning and warrants more research and monitoring protocols."

Acute Kidney Injury • Chronic Kidney Disease • Constipation • Diabetes • Diabetic Nephropathy • Gastroenterology • Gastrointestinal Disorder • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

An unusual presentation of acute kidney injury secondary to Influenza A-induced rhabdomyolysis (UKKW 2026) - "Oseltamivir was initiated but subsequently withdrawn as symptom duration exceeded 7 days...The patient transferred to the intensive care unit for management of a hypertensive emergency, requiring labetalol infusion, amlodipine, doxazosin, clonidine and furosemide for blood pressure control... This case illustrates a rare but serious complication of influenza infection and highlights the importance of screening for influenza virus in the setting of non-traumatic rhabdomyolysis, even in those without typical symptoms and outside of the usual flu season."

Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Hepatology • Immunology • Infectious Disease • Influenza • Liver Failure • Lupus Nephritis • Musculoskeletal Diseases • Myocardial Infarction • Myositis • Nephrology • Renal Disease • Respiratory Diseases

Doxazosin Alleviates Chronic Orofacial Pain. (PubMed, Int J Mol Sci) - "These sexually dimorphic contradictions further complicate the understanding of the noradrenergic system's involvement in nociception. The findings indicate that by reducing NAα1 receptor drive with doxazosin, the role of the locus coeruleus can be shifted back to NAα2-receptor-mediated pain inhibition."

Journal • Immunology • Mood Disorders • Pain • Psychiatry • CTSB • GFAP • PPBP

Sexual function outcomes of the 5-year treatment with Rezum compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial (AUA 2026) - No abstract available

Benign Prostatic Hyperplasia

Effects of Prazosin and Other Alpha-1 Adrenergic Antagonist Drugs on Nightmares and Sleep Disturbances in Posttraumatic Stress Disorder. (PubMed, J Clin Psychopharmacol) - "When available and clinically tolerated, prazosin continues to have the best evidence base for use in PTSD-related nightmares. When prazosin use is not feasible, alternative alpha-1 blockers may be effective in a subset of patients."

Journal • Alzheimer's Disease • Behavior Disorders • CNS Disorders • Cognitive Disorders • Depression • Insomnia • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder • Substance Abuse

Anterior segment, static and dynamic pupillography changes in patients using different types of alpha-1 blockers. (PubMed, Doc Ophthalmol) - "The alpha-1 blockers included in this study were those most commonly used in clinical practice. Our results showed that, as aspected, alpha-1 blockers do not change the anterior segment. Three of the groups showed no abnormal pupil behaviour, but the diameter was significantly smaller in the doxazosin group."

Journal • Benign Prostatic Hyperplasia

What is the Cost of Selectivity? Selective and Nonselective Alpha Blockade Costs Associated with Adrenalectomy for Pheochromocytoma. (PubMed, Ann Surg Oncol) - "When compared with nonselective alpha blockers, selective alpha blockers are associated with lower medication costs but equivalent hospitalization and post-hospitalization costs."

Journal • Critical care • Oncology • Solid Tumor

Exploring lactoferrin as an innovative covalently immobilized chiral selector for the selective separation of pharmaceutical enantiomers using HPLC. (PubMed, Anal Chim Acta) - "HPLC remains the primary choice for all pharmaceutical research, as it offers higher sensitivity, reliability, and reproducibility. This work introduces LF as a novel, multifunctional CS for HPLC, covalently immobilized for the first time, expanding the toolbox of protein-based chiral stationary phases. Moreover, the study also offers a critical insight into the limitations of relying solely on computational predictions, empirically demonstrating that solvent effects can override binding affinities, a phenomenon not captured by standard docking simulations."

Journal

Doxazosin for the treatment of mental health disorders: A scoping review. (PubMed, PLOS Ment Health) - "Although prazosin is the most well-known alpha-1 antagonist used for these disorders, doxazosin has a longer half-life, which allows for more convenient once-daily dosing. Current clinical trials continue to be focused on PTSD and cocaine use disorder, given promising evidence. More randomized controlled trials need to be completed for recommendations of doxazosin's use for other PTSD hyperarousal symptoms (e.g., flashbacks, intrusive thoughts) and other substance use disorders, including nicotine and alcohol use disorders."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Doxazosin as an adjunct to trauma-focused cognitive behavioral therapy for the treatment of posttraumatic nightmares (PubMed, Nervenarzt) - No abstract available

Journal • Review • Mood Disorders

Prolonged alpha-blockade and doxazosin are associated with hypertensive crisis in pheochromocytoma surgery. (PubMed, Front Endocrinol (Lausanne)) - "Selective α-blockade with doxazosin resulted in longer hypertensive crises, increased intraoperative vasopressor requirements, and prolonged hospitalization. Prolonged α-blockade (>30 days) was associated with more frequent and prolonged hypertensive crises and a higher risk of postoperative vasopressor use."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Oncology • Solid Tumor

Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis. (PubMed, Int Neurourol J) - "This study found no significant association between the use of alpha-blockers or 5ARIs and increased dementia risk. These findings may assist clinicians in making more informed prescribing decisions, particularly for older male patients with BPH. Further large-scale research with extended follow-up periods is needed to strengthen the evidence across all BPH medications."

Journal • Retrospective data • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia

Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025. (PubMed, Arab J Urol) - "Network meta-analysis revealed efficacy ranking favoring at first terazosin, followed by doxazosin then, silodosin then, tamsulosin then, alfuzosin and last the least effective was naftopidil. While tamsulosin remains the most studied agent, our network meta-analysis suggests terazosin and doxazosin may offer superior efficacy. The favorable risk-benefit profile supports routine use of alpha-blockers for appropriately selected patients with ureteral stones."

Journal • Retrospective data • Review • Pain • Renal Calculi • Urolithiasis

Sexual function outcomes of the 5-year treatment with Rezum compared to doxazosin, finasteride and combination drug therapy for men with BPH: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. (EAU 2026) - No abstract available

Benign Prostatic Hyperplasia

Doxazosin versus tamsulosin for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic literature review and network meta-analysis. (PubMed, World J Urol) - No abstract available

Journal • Retrospective data • Review • Benign Prostatic Hyperplasia

A Systematic Review and Meta-Analysis of Doxazosin Pharmacokinetics in Healthy and Diseased Populations. (PubMed, Pharmaceuticals (Basel)) - "Despite normalization, substantial variability remained in AUC and Cmax, related in part to ethnicity, hepatic impairment, dosage formulation, and body weight. While pooled estimates offer valuable summary reference points, the high heterogeneity and evidence of small-study effects highlight the need for more standardized PK trials and patient-level analyses to better support individualized dosing strategies."

Journal • PK/PD data • Retrospective data • Benign Prostatic Hyperplasia • Cardiovascular • Hepatology • Hypertension